Harvard team converts pancreatic cells into insulin‑producing cells by disabling gene brake

Diabetes, both type 1 and type 2, stems from a deficiency of pancreatic beta (β) cells that produce insulin to regulate blood‑sugar levels. In a recent study, scientists at Harvard Medical School reported a method to convert a patient’s own pancreatic cells into insulin‑producing cells by modifying a single gene. The approach aims to restore endogenous insulin production without the need for donor tissue or external cell transplantation.

The researchers identified a genetic switch that, when activated, reprograms exocrine pancreatic cells—normally involved in digestive enzyme secretion—into functional β‑like cells capable of synthesizing and releasing insulin in response to glucose. Laboratory experiments demonstrated that the newly formed cells exhibit key markers of mature β cells and can normalize blood‑glucose levels in diabetic mouse models. The technique relies on precise gene editing tools to ensure targeted activation while minimizing off‑target effects.

If the findings translate to human subjects, the strategy could provide a durable, autologous therapy for diabetes, reducing dependence on insulin injections and mitigating complications associated with current treatments. The team plans to advance the work toward pre‑clinical safety studies, with the goal of initiating clinical trials to evaluate efficacy and long‑term outcomes in patients.